Merck beat earnings expectations, earnt 83 cents per share, analysts expected 77.
Of interest to CSL holders:
"Merck's cervical cancer vaccine, GARDASIL (human papillomavirus (HPV) quadrivalent (types 6, 11, 16, 18) vaccine, recombinant), posted total sales as recorded by Merck of $268 million for the second quarter of 2009, an 18 percent decline from the same quarter in 2008. Vaccines in most major European markets are sold through the company’s joint venture, Sanofi Pasteur MSD, and the results from the company's interest in the joint venture are recorded in equity income from affiliates. "
I know sales were expected to be down this year, just trying to find out if this matches expectations. Also that part about European sales obscures what the total GARDASIL sales world wide for Merck was.
merck report
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$311.12 |
Change
3.100(1.01%) |
Mkt cap ! $150.3B | |||
| Open | High | Low | Value | Volume |
| $308.75 | $311.12 | $306.32 | $220.9M | 712.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1100 | $310.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $311.13 | 1131 | 2 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |